ArticlePLoS genetics2016
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity.
Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- The GATA3-RFPL3-ASK1 axis suppresses breast cancer growth and lung metastasis.Apoptosis : an international journal on programmed cell death · 2026Article
- Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.Breast cancer research and treatment · 2025Article
- Divergent ERα co-factor landscapes in gynecological cancers: implications for disease progression and therapy.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2025Review
- KLF transcription factors in bone diseases.Journal of cellular and molecular medicine · 2024Review
- Case report: Near-complete response to neratinib-based treatment in HR-positiveFrontiers in oncology · 2024Article
- Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell lines.Journal of cancer research and clinical oncology · 2023Article
- GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.Communications biology · 2022Article
- GATA3 Truncation Mutants Alter EMT Related Gene ExpressionFrontiers in genetics · 2022Article
- Rare and potentially pathogenic variants in hydroxycarboxylic acid receptor genes identified in breast cancer cases.BMC medical genomics · 2021Article
- The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer.Current opinion in structural biology · 2021Review
- Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.Breast cancer research and treatment · 2021Article
- Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes.BMC bioinformatics · 2021Article
- GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.Scientific reports · 2021Article
- Role of GATA3 exon 6 germline mutations in breast cancer progression in Egyptian female patients.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Whole Exome Sequencing in the Male Breast Cancer with Prolactinoma: A Case Report and Literature Review.Journal of breast cancer · 2020Article
- Structural and conformational changes induced by missense variants in the zinc finger domains of GATA3 involved in breast cancer.RSC advances · 2020Article
- Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.Breast cancer research and treatment · 2020Article
- A pan-cancer analysis reveals nonstop extension mutations causing SMAD4 tumour suppressor degradation.Nature cell biology · 2020Article
- Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.Nucleic acids research · 2020Article
- MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling.The Journal of biological chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
Patterns of somatic mutations in cancer genes provide information about their functional role in tumourigenesis, and thus indicate their potential for therapeutic exploitation. Yet, the classical distinction between oncogene and tumour suppressor may not always apply. For instance, TP53 has been simultaneously associated with tumour suppressing and promoting activities. Here, we uncover a similar phenomenon for GATA3, a frequently mutated, yet poorly understood, breast cancer gene. We identify two functional classes of frameshift mutations that are associated with distinct expression profiles in tumours, differential disease-free patient survival and gain- and loss-of-function activities in a cell line model. Furthermore, we find an estrogen receptor-independent synthetic lethal interaction between a GATA3 frameshift mutant with an extended C-terminus and the histone methyltransferases G9A and GLP, indicating perturbed epigenetic regulation. Our findings reveal important insights into mutant GATA3 function and breast cancer, provide the first potential therapeutic strategy and suggest that dual tumour suppressive and oncogenic activities are more widespread than previously appreciated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.